Cargando…
Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein
COVID-19 is an emerging disease that poses a severe threat to global public health. As such, there is an urgent demand for vaccines against SARS-CoV-2, the virus that causes COVID-19. Here, we describe a virus-like nanoparticle candidate vaccine against SARS-CoV-2 produced by an E. coli expression s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Microbiology and Biotechnology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668089/ https://www.ncbi.nlm.nih.gov/pubmed/36224764 http://dx.doi.org/10.4014/jmb.2205.05023 |
_version_ | 1784831837915316224 |
---|---|
author | Zhou, Yong-Fei Nie, Jiao-Jiao Shi, Chao Ning, Ke Cao, Yu-Feng Xie, Yanbo Xiang, Hongyu Xie, Qiuhong |
author_facet | Zhou, Yong-Fei Nie, Jiao-Jiao Shi, Chao Ning, Ke Cao, Yu-Feng Xie, Yanbo Xiang, Hongyu Xie, Qiuhong |
author_sort | Zhou, Yong-Fei |
collection | PubMed |
description | COVID-19 is an emerging disease that poses a severe threat to global public health. As such, there is an urgent demand for vaccines against SARS-CoV-2, the virus that causes COVID-19. Here, we describe a virus-like nanoparticle candidate vaccine against SARS-CoV-2 produced by an E. coli expression system. The fusion protein of a truncated ORF2-encoded protein of aa 439~608 (p170) from hepatitis E virus CCJD-517 and the receptor-binding domain of the spike protein from SARS-CoV-2 were expressed, purified and characterized. The antigenicity and immunogenicity of p170-RBD were evaluated in vitro and in Kunming mice. Our investigation revealed that p170-RBD self-assembled into approximately 24 nm virus-like particles, which could bind to serum from vaccinated people (p < 0.001) and receptors on cells. Immunization with p170-RBD induced the titer of IgG antibody vaccine increased from 14 days post-immunization and was significantly enhanced after a booster immunization at 28 dpi, ultimately reaching a peak level on 42 dpi with a titer of 4.97 log(10). Pseudovirus neutralization tests showed that the candidate vaccine induced a strong neutralizing antibody response in mice. In this research, we demonstrated that p170-RBD possesses strong antigenicity and immunogenicity and could be a potential candidate for use in future SARS-CoV-2 vaccine development. |
format | Online Article Text |
id | pubmed-9668089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Korean Society for Microbiology and Biotechnology |
record_format | MEDLINE/PubMed |
spelling | pubmed-96680892022-12-13 Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein Zhou, Yong-Fei Nie, Jiao-Jiao Shi, Chao Ning, Ke Cao, Yu-Feng Xie, Yanbo Xiang, Hongyu Xie, Qiuhong J Microbiol Biotechnol Research article COVID-19 is an emerging disease that poses a severe threat to global public health. As such, there is an urgent demand for vaccines against SARS-CoV-2, the virus that causes COVID-19. Here, we describe a virus-like nanoparticle candidate vaccine against SARS-CoV-2 produced by an E. coli expression system. The fusion protein of a truncated ORF2-encoded protein of aa 439~608 (p170) from hepatitis E virus CCJD-517 and the receptor-binding domain of the spike protein from SARS-CoV-2 were expressed, purified and characterized. The antigenicity and immunogenicity of p170-RBD were evaluated in vitro and in Kunming mice. Our investigation revealed that p170-RBD self-assembled into approximately 24 nm virus-like particles, which could bind to serum from vaccinated people (p < 0.001) and receptors on cells. Immunization with p170-RBD induced the titer of IgG antibody vaccine increased from 14 days post-immunization and was significantly enhanced after a booster immunization at 28 dpi, ultimately reaching a peak level on 42 dpi with a titer of 4.97 log(10). Pseudovirus neutralization tests showed that the candidate vaccine induced a strong neutralizing antibody response in mice. In this research, we demonstrated that p170-RBD possesses strong antigenicity and immunogenicity and could be a potential candidate for use in future SARS-CoV-2 vaccine development. The Korean Society for Microbiology and Biotechnology 2022-10-28 2022-09-19 /pmc/articles/PMC9668089/ /pubmed/36224764 http://dx.doi.org/10.4014/jmb.2205.05023 Text en Copyright © 2022 by the authors. Licensee KMB. https://creativecommons.org/licenses/by/4.0/This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research article Zhou, Yong-Fei Nie, Jiao-Jiao Shi, Chao Ning, Ke Cao, Yu-Feng Xie, Yanbo Xiang, Hongyu Xie, Qiuhong Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein |
title | Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein |
title_full | Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein |
title_fullStr | Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein |
title_full_unstemmed | Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein |
title_short | Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein |
title_sort | expression and immunogenicity of sars-cov-2 virus-like particles based on recombinant truncated hev-3 orf2 capsid protein |
topic | Research article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668089/ https://www.ncbi.nlm.nih.gov/pubmed/36224764 http://dx.doi.org/10.4014/jmb.2205.05023 |
work_keys_str_mv | AT zhouyongfei expressionandimmunogenicityofsarscov2viruslikeparticlesbasedonrecombinanttruncatedhev3orf2capsidprotein AT niejiaojiao expressionandimmunogenicityofsarscov2viruslikeparticlesbasedonrecombinanttruncatedhev3orf2capsidprotein AT shichao expressionandimmunogenicityofsarscov2viruslikeparticlesbasedonrecombinanttruncatedhev3orf2capsidprotein AT ningke expressionandimmunogenicityofsarscov2viruslikeparticlesbasedonrecombinanttruncatedhev3orf2capsidprotein AT caoyufeng expressionandimmunogenicityofsarscov2viruslikeparticlesbasedonrecombinanttruncatedhev3orf2capsidprotein AT xieyanbo expressionandimmunogenicityofsarscov2viruslikeparticlesbasedonrecombinanttruncatedhev3orf2capsidprotein AT xianghongyu expressionandimmunogenicityofsarscov2viruslikeparticlesbasedonrecombinanttruncatedhev3orf2capsidprotein AT xieqiuhong expressionandimmunogenicityofsarscov2viruslikeparticlesbasedonrecombinanttruncatedhev3orf2capsidprotein |